poisar

Stocks · News reference

HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Raises Price Target to $165

Benzinga Newsdesk

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Corcept Therapeutics (NASDAQ:CORT) with a Buy and raises the price target from $95 to $165.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

CORT
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike

    With Wall Street experiencing volatility due to Middle East tensions and inflation concerns, the Federal Reserve has raised interest rates for the first time in three years and hints at further hikes. The article recommends four low-beta defensive healthcare stocks as potential investments during this uncertain period: Abbott Laboratories, Corcept Therapeutics, Precigen, and Bausch Health Companies.

    ABTCORTPGENBHC
  2. SEC EDGAR

    8-K filing — CORCEPT THERAPEUTICS INC (CORT)

    Filed: 2026-09-23 AccNo: 0001193125-26-398561 Size: 161 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

    CORT